Business Wire

CGTN

23.3.2021 20:21:13 CET | Business Wire | Press release

Share
CGTN: Xi's Fujian Tour: Forestry, Healthcare, Rural Revitalization

Forestry reform, reform of the medical and healthcare system, and rural revitalization were highlighted in Chinese President Xi Jinping's second day of his inspection tour in east China's Fujian Province on Tuesday.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005995/en/

Visiting the Shaxian District of Sanming City on Tuesday, Xi went to an assets and equity exchange to learn about local efforts to deepen reform of the forest tenure system and a hospital to learn about local reform of the medical and healthcare system.

He also went to a village to inspect work on promoting rural revitalization.

'Lush mountains and lucid waters are valuable assets'

In the past, Chinese farmers were excluded from collective forestry and shared few timber revenues. As a result, they lacked the incentives to protect forests, and timber theft was rampant.

To solve these problems, Fujian Province launched the reform to decentralize the collective forest tenure system in favor of individual (household) management in 2003, which is also considered the start of China's new round of forest tenure reform.

It echoed Xi's instruction to develop forestry as an industry while maintaining its ecological functions when he worked in Fujian.

Xi had visited Sanming City 11 times when he worked in Fujian. During a trip to the city in June 2002, when he was Fujian governor, Xi emphasized that environmental development was of paramount importance.

He said at the time that it might seem that green mountains and lucid waters are of little value, but in the long term, they are valuable assets. He also urged local officials to transform economic growth and avoid wasting resources and damaging the environment.

To carry out Xi's instructions, local authorities further explored a number of reform measures, including taking steps to encourage farmers to transfer their timberland to forest cooperatives and other operators and issuing more loans to forestry businesses to solve their financial problems.

The total output value of forestry reached 114.6 billion yuan in 2019 in Sanming. The city's forest coverage is expected to exceed 80 percent in 2020.

Progress in the reform of the medical and healthcare system

Xi also visited the Shaxian General Hospital in Sanming City to learn about the local medical and healthcare system's reform.

Shaxian General Hospital has jurisdiction over 12 grass-roots branch hospitals and 128 extended village health clinics. Its establishment is also one of the measures to reform the local medical and health system.

Xi has paid close attention to the country's medical reform progress, and praised Sanming's medical advancement at several key meetings.

At the 33rd meeting of the central leading group for deepening overall reform on March 24, 2017, Xi hailed Sanming's experience in medical reform. He said Sanming's medical reform is in the right direction and has produced obvious results, urging promotion of Sanming's practice nationwide.

Shaxian snacks and rural revitalization

Xi has put forward ardent hopes for the development of Shaxian snacks many times, and on Tuesday, he visited the Yubang Village, which is famous for Shaxian snacks, to inspect work on promoting rural revitalization there.

Hailing from Shaxian, popular restaurant chain Shaxian Snacks is renowned for its pork wontons, peanut sauce noodles, and over 100 other local-flavor delicacies.

Starting with a single booth in a street market, the chain now has more than 88,000 chain stores in China and 62 other countries and regions, pulling in a hefty revenue exceeding 50 billion yuan ($7.6 billion).

Thus far, the Shaxian Snacks trademark has been approved by eight countries: Japan, New Zealand, Malaysia, Indonesia, the Philippines, South Korea, Singapore, and Australia. The Shaxian Snacks stores entered 62 countries, including the U.S., Germany, and Portugal. In three hours, the first store in New York sold out and sales revenue of the first store in Tokyo reached nearly $2,000 in 5 hours. After dominating China, it's now aiming at a bigger market and a brighter future.

https://news.cgtn.com/news/2021-03-23/Xi-Jinping-inspects-Shaxian-County-in-Fujian-Province-YS2YqEdq36/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye